Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.

Sci Rep · 2018 · PMC5862986 · PMID 29563546

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

4E ) showed that tissue phosphorylation was inhibited in the V565 treated cultures with a clear trend for greater inhibition at higher V565 concentrations, reaching 68% inhibition at 300 nM V565 relative to the control VHH.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.